^
Association details:
| Biomarker: | MCL1 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + S63845 (MCL1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TARGETING ANTI-APOPTOTIC MCL1 PROTEIN WITH S63845 IS HIGHLY EFFECTIVE IN AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS WITH NON-EXPRESSION OF BCL2
Published date:
06/12/2020
Excerpt:
...single-agent S63845 was highly effective in BCL2-negative lymphomas and that co-targeting of MCL1 and BCL2 (with S63845 and venetoclax) induced additive to synergistic anti-lymphoma effect in all tested PDX models.
